Pathways in cancer

Human Diseases; Cancers

Weinberg RA.

The biology of cancer

Garland Science, Taylor & Francis Group, LLC (2007)

PMID:10647931

Hanahan D, Weinberg RA

The hallmarks of cancer.

Cell 100:57-70 (2000)

PMID:15000146

Grady WM.

Genomic instability and colon cancer.

Cancer Metastasis Rev 23:11-27 (2004)

PMID:16555243

Soreide K, Janssen EA, Soiland H, Korner H, Baak JP.

Microsatellite instability in colorectal cancer.

Br J Surg 93:395-406 (2006)

PMID:11078609

Anwar S, Hall C, White J, Deakin M, Farrell W, Elder JB.

Hereditary non-polyposis colorectal cancer: an updated review.

Eur J Surg Oncol 26:635-45 (2000)

PMID:16699851

Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y.

Colorectal cancer: genetics of development and metastasis.

J Gastroenterol 41:185-92 (2006)

PMID:12621137

Lynch HT, de la Chapelle A.

Hereditary colorectal cancer.

N Engl J Med 348:919-32 (2003)

PMID:12951588

Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C.

The significance of unstable chromosomes in colorectal cancer.

Nat Rev Cancer 3:695-701 (2003)

PMID:10505543

Behrens J.

Cadherins and catenins: role in signal transduction and tumor progression.

Cancer Metastasis Rev 18:15-30 (1999)

PMID:16042571

Behrens J.

The role of the Wnt signalling pathway in colorectal tumorigenesis.

Biochem Soc Trans 33:672-5 (2005)

PMID:15349822

Behrens J, Lustig B.

The Wnt connection to tumorigenesis.

Int J Dev Biol 48:477-87 (2004)

PMID:9196022

Polakis P.

The adenomatous polyposis coli (APC) tumor suppressor.

Biochim Biophys Acta 1332:F127-47 (1997)

PMID:12737309

Janssen KP.

Murine models of colorectal cancer: studying the role of oncogenic K-ras.

Cell Mol Life Sci 60:495-506 (2003)

PMID:11459867

Adjei AA.

Blocking oncogenic Ras signaling for cancer therapy.

J Natl Cancer Inst 93:1062-74 (2001)

PMID:15573119

Arakawa H.

Netrin-1 and its receptors in tumorigenesis.

Nat Rev Cancer 4:978-87 (2004)

PMID:15310786

Mehlen P, Fearon ER.

Role of the dependence receptor DCC in colorectal cancer pathogenesis.

J Clin Oncol 22:3420-8 (2004)

PMID:11223406

Peltomaki P.

DNA mismatch repair and cancer.

Mutat Res 488:77-85 (2001)

PMID:15711891

Li F, Cao Y, Townsend CM Jr, Ko TC.

TGF-beta signaling in colon cancer cells.

World J Surg 29:306-11 (2005)

PMID:11170304

Roman C, Saha D, Beauchamp R.

TGF-beta and colorectal carcinogenesis.

Microsc Res Tech 52:450-7 (2001)

PMID:16326109

Watson AJ.

An overview of apoptosis and the prevention of colorectal cancer.

Crit Rev Oncol Hematol 57:107-21 (2006)

PMID:15479695

Watson AJ.

Apoptosis and colorectal cancer.

Gut 53:1701-9 (2004)

PMID:11477132

Houlston RS.

What we could do now: molecular pathology of colorectal cancer.

Mol Pathol 54:206-14 (2001)

Von Hoff DD, Evans DB, Hruban RH (ed).

Pancreatic Cancer

Jones and bartlett publishers (2005)

Niitsu Y, Yokota J (ed).

[Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese)

Nankodo (1999)

PMID:12459728

Bardeesy N, DePinho RA.

Pancreatic cancer biology and genetics.

Nat Rev Cancer 2:897-909 (2002)

PMID:11407945

Bardeesy N, Sharpless NE, DePinho RA, Merlino G.

The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.

Semin Cancer Biol 11:201-18 (2001)

PMID:12946833

Cowgill SM, Muscarella P.

The genetics of pancreatic cancer.

Am J Surg 186:279-86 (2003)

PMID:16702400

Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.

Genetics and biology of pancreatic ductal adenocarcinoma.

Genes Dev 20:1218-49 (2006)

PMID:10740269

Shields JM, Pruitt K, McFall A, Shaub A, Der CJ.

Understanding Ras: 'it ain't over 'til it's over'.

Trends Cell Biol 10:147-54 (2000)

PMID:12648469

Holbro T, Civenni G, Hynes NE.

The ErbB receptors and their role in cancer progression.

Exp Cell Res 284:99-110 (2003)

PMID:14967450

Marmor MD, Skaria KB, Yarden Y.

Signal transduction and oncogenesis by ErbB/HER receptors.

Int J Radiat Oncol Biol Phys 58:903-13 (2004)

PMID:14586404

DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.

Oncogene 22:7781-95 (2003)

PMID:12545153

Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Oncogene 22:319-29 (2003)

PMID:14580692

Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M.

Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.

Cancer Lett 201:107-16 (2003)

PMID:12079267

Schmid RM.

Genetic basis of pancreatic cancer.

Best Pract Res Clin Gastroenterol 16:421-33 (2002)

PMID:15774796

Elliott RL, Blobe GC.

Role of transforming growth factor Beta in human cancer.

J Clin Oncol 23:2078-93 (2005)

PMID:15823750

Rudkin TM, Foulkes WD.

BRCA2: breaks, mistakes and failed separations.

Trends Mol Med 11:145-8 (2005)

PMID:11707511

Venkitaraman AR.

Functions of BRCA1 and BRCA2 in the biological response to DNA damage.

J Cell Sci 114:3591-8 (2001)

PMID:15639402

Soni D, King JA, Kaye AH, Hovens CM.

Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge.

J Clin Neurosci 12:1-5 (2005)

PMID:12154354

Zhu Y, Parada LF.

The molecular and genetic basis of neurological tumours.

Nat Rev Cancer 2:616-26 (2002)

PMID:11253051

Holland EC.

Gliomagenesis: genetic alterations and mouse models.

Nat Rev Genet 2:120-9 (2001)

PMID:16700615

Bansal K, Liang ML, Rutka JT.

Molecular biology of human gliomas.

Technol Cancer Res Treat 5:185-94 (2006)

Tabuchi K (ed).

[Gliomas: Research and therapy] (In Japanese)

Springer-Verlag Tokyo (2006)

PMID:12762887

Kapoor GS, O'Rourke DM.

Mitogenic signaling cascades in glial tumors.

Neurosurgery 52:1425-34; discussion 1434-5 (2003)

PMID:16095998

Hulleman E, Helin K.

Molecular mechanisms in gliomagenesis.

Adv Cancer Res 94:1-27 (2005)

PMID:11057895

Schlessinger J.

Cell signaling by receptor tyrosine kinases.

Cell 103:211-25 (2000)

PMID:9643506

Ng HK, Lam PY.

The molecular genetics of central nervous system tumors.

Pathology 30:196-202 (1998)

PMID:12084351

Knobbe CB, Merlo A, Reifenberger G.

Pten signaling in gliomas.

Neuro-oncol 4:196-211 (2002)

PMID:16557281

Kondo T, Ezzat S, Asa SL.

Pathogenetic mechanisms in thyroid follicular-cell neoplasia.

Nat Rev Cancer 6:292-306 (2006)

PMID:16551846

Chiloeches A, Marais R.

Is BRAF the Achilles' Heel of thyroid cancer?

Clin Cancer Res 12:1661-4 (2006)

PMID:16946003

Reddi HV, McIver B, Grebe SK, Eberhardt NL.

THE PAX8/PPAR{gamma} ONCOGENE IN THYROID TUMORIGENESIS.

Endocrinology : (2006)

PMID:17062879

Santoro M, Melillo RM, Fusco A.

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

Eur J Endocrinol 155:645-653 (2006)

PMID:16242838

Pierotti MA, Greco A.

Oncogenic rearrangements of the NTRK1/NGF receptor.

Cancer Lett 232:90-8 (2006)

PMID:16189702

Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P.

Molecular pathology of well-differentiated thyroid carcinomas.

Virchows Arch 447:787-93 (2005)

PMID:11165748

Gimm O.

Thyroid cancer.

Cancer Lett 163:143-56 (2001)

PMID:12094241

Williams D.

Cancer after nuclear fallout: lessons from the Chernobyl accident.

Nat Rev Cancer 2:543-9 (2002)

PMID:16236521

Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H.

The molecular pathogenesis of acute myeloid leukemia.

Crit Rev Oncol Hematol 56:195-221 (2005)

PMID:12563308

Tenen DG.

Disruption of differentiation in human cancer: AML shows the way.

Nat Rev Cancer 3:89-101 (2003)

PMID:16146838

Choudhary C, Muller-Tidow C, Berdel WE, Serve H.

Signal transduction of oncogenic Flt3.

Int J Hematol 82:93-9 (2005)

PMID:12951584

Stirewalt DL, Radich JP.

The role of FLT3 in haematopoietic malignancies.

Nat Rev Cancer 3:650-65 (2003)

PMID:16642045

Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L.

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Leukemia 20:911-28 (2006)

PMID:15625120

Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R.

Normal and oncogenic forms of the receptor tyrosine kinase kit.

Stem Cells 23:16-43 (2005)

PMID:11721960

Lorsbach RB, Downing JR.

The role of the AML1 transcription factor in leukemogenesis.

Int J Hematol 74:258-65 (2001)

PMID:12468433

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Blood 101:3164-73 (2003)

PMID:17554387

Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C.

The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.

Leukemia : (2007)

PMID:16352814

Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG.

ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.

Blood 107:3330-8 (2006)

PMID:15719031

Ren R.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Nat Rev Cancer 5:172-83 (2005)

PMID:11071626

Deininger MW, Goldman JM, Melo JV.

The molecular biology of chronic myeloid leukemia.

Blood 96:3343-56 (2000)

PMID:14982876

Calabretta B, Perrotti D.

The biology of CML blast crisis.

Blood 103:4010-22 (2004)

PMID:10403855

Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.

The biology of chronic myeloid leukemia.

N Engl J Med 341:164-72 (1999)

PMID:15156182

Mitani K.

Molecular mechanisms of leukemogenesis by AML1/EVI-1.

Oncogene 23:4263-9 (2004)

PMID:16484590

Dong M, Blobe GC.

Role of transforming growth factor-beta in hematologic malignancies.

Blood 107:4589-96 (2006)

PMID:9834202

Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.

The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.

Blood 92:4003-12 (1998)

PMID:12801837

Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.

Haematologica 88:622-30 (2003)

PMID:11160144

Baldwin AS.

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

J Clin Invest 107:241-6 (2001)

PMID:12244301

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Nat Med 8:1145-52 (2002)

PMID:15948971

Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC.

Molecular aetiology and pathogenesis of basal cell carcinoma.

Br J Dermatol 152:1108-24 (2005)

PMID:12588368

Saldanha G, Fletcher A, Slater DN.

Basal cell carcinoma: a dermatopathological and molecular biological update.

Br J Dermatol 148:195-202 (2003)

PMID:15978322

Daya-Grosjean L, Couve-Privat S.

Sonic hedgehog signaling in basal cell carcinomas.

Cancer Lett 225:181-92 (2005)

PMID:15468170

Tsai KY, Tsao H.

The genetics of skin cancer.

Am J Med Genet C Semin Med Genet 131C:82-92 (2004)

PMID:16881963

Athar M, Tang X, Lee JL, Kopelovich L, Kim AL.

Hedgehog signalling in skin development and cancer.

Exp Dermatol 15:667-77 (2006)

PMID:16306523

Rubin AI, Chen EH, Ratner D.

Basal-cell carcinoma.

N Engl J Med 353:2262-9 (2005)

PMID:11276000

Saldanha G.

The Hedgehog signalling pathway and cancer.

J Pathol 193:427-32 (2001)

PMID:15270885

Saldanha G, Ghura V, Potter L, Fletcher A.

Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.

Br J Dermatol 151:157-64 (2004)

PMID:14737121

Pasca di Magliano M, Hebrok M.

Hedgehog signalling in cancer formation and maintenance.

Nat Rev Cancer 3:903-11 (2003)

PMID:15656799

Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G.

Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.

Br J Dermatol 152:43-51 (2005)

PMID:14556242

Cohen MM Jr.

The hedgehog signaling network.

Am J Med Genet A 123:5-28 (2003)

PMID:11736900

Yamazaki F, Aragane Y, Kawada A, Tezuka T.

Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma.

Br J Dermatol 145:771-7 (2001)

PMID:16054233

Erb P, Ji J, Wernli M, Kump E, Glaser A, Buchner SA.

Role of apoptosis in basal cell and squamous cell carcinoma formation.

Immunol Lett 100:68-72 (2005)

PMID:11130178

Toftgard R.

Hedgehog signalling in cancer.

Cell Mol Life Sci 57:1720-31 (2000)

PMID:16822996

Miller AJ, Mihm MC Jr.

Melanoma.

N Engl J Med 355:51-65 (2006)

PMID:12894244

Chin L.

The genetics of malignant melanoma: lessons from mouse and man.

Nat Rev Cancer 3:559-70 (2003)

PMID:16750612

Takata M, Saida T.

Genetic alterations in melanocytic tumors.

J Dermatol Sci 43:1-10 (2006)

PMID:15841168

Chudnovsky Y, Khavari PA, Adams AE.

Melanoma genetics and the development of rational therapeutics.

J Clin Invest 115:813-24 (2005)

PMID:16001050

Merlino G.

Cancer biology: the weakest link?

Nature 436:33-5 (2005)

PMID:16001072

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Nature 436:117-22 (2005)

PMID:16899407

Levy C, Khaled M, Fisher DE.

MITF: master regulator of melanocyte development and melanoma oncogene.

Trends Mol Med 12:406-14 (2006)

PMID:15009714

Tsao H, Goel V, Wu H, Yang G, Haluska FG.

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

J Invest Dermatol 122:337-41 (2004)

PMID:11224709

Gruss C, Herlyn M.

Role of cadherins and matrixins in melanoma.

Curr Opin Oncol 13:117-23 (2001)

PMID:15721476

Thompson JF, Scolyer RA, Kefford RF.

Cutaneous melanoma.

Lancet 365:687-701 (2005)

PMID:14695152

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Clin Cancer Res 9:6483-8 (2003)

PMID:15557758

Hussein MR.

The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?

Tumour Biol 25:200-7 (2004)

PMID:10843728

Lazar-Molnar E, Hegyesi H, Toth S, Falus A.

Autocrine and paracrine regulation by cytokines and growth factors in melanoma.

Cytokine 12:547-54 (2000)

PMID:16339096

Cohen HT, McGovern FJ.

Renal-cell carcinoma.

N Engl J Med 353:2477-90 (2005)

PMID:15122209

Pavlovich CP, Schmidt LS.

Searching for the hereditary causes of renal-cell carcinoma.

Nat Rev Cancer 4:381-93 (2004)

PMID:14634372

Linehan WM, Walther MM, Zbar B.

The genetic basis of cancer of the kidney.

J Urol 170:2163-72 (2003)

PMID:14685170

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.

Met, metastasis, motility and more.

Nat Rev Mol Cell Biol 4:915-25 (2003)

PMID:15611513

Kim WY, Kaelin WG.

Role of VHL gene mutation in human cancer.

J Clin Oncol 22:4991-5004 (2004)

PMID:17211469

Sudarshan S, Linehan WM, Neckers L.

HIF and fumarate hydratase in renal cancer.

Br J Cancer 96:403-7 (2007)

PMID:17287871

Sudarshan S, Pinto PA, Neckers L, Linehan WM.

Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.

Nat Clin Pract Urol 4:104-10 (2007)

PMID:12351585

Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.

Understanding familial and non-familial renal cell cancer.

Hum Mol Genet 11:2489-98 (2002)

PMID:17158541

Mitra AP, Datar RH, Cote RJ.

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

J Clin Oncol 24:5552-64 (2006)

PMID:16474624

Wolff EM, Liang G, Jones PA.

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

Nat Clin Pract Urol 2:502-10 (2005)

PMID:16110317

Wu XR.

Urothelial tumorigenesis: a tale of divergent pathways.

Nat Rev Cancer 5:713-25 (2005)

PMID:11103787

Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R.

Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors.

Cancer Res 60:6298-302 (2000)

PMID:12850530

Bellmunt J, Hussain M, Dinney CP.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Crit Rev Oncol Hematol 46 Suppl:S85-104 (2003)

PMID:17149381

Sugano K, Kakizoe T.

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.

Nat Clin Pract Urol 3:642-52 (2006)

PMID:15746962

Dunn KL, Espino PS, Drobic B, He S, Davie JR.

The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.

Biochem Cell Biol 83:1-14 (2005)

PMID:15551095

Williams SG, Stein JP.

Molecular pathways in bladder cancer.

Urol Res 32:373-85 (2004)

PMID:12878745

Nelson WG, De Marzo AM, Isaacs WB.

Prostate cancer.

N Engl J Med 349:366-81 (2003)

PMID:15724144

Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.

The emerging role of the PI3-K-Akt pathway in prostate cancer progression.

Prostate Cancer Prostatic Dis 8:108-18 (2005)

PMID:16551847

Pienta KJ, Bradley D.

Mechanisms underlying the development of androgen-independent prostate cancer.

Clin Cancer Res 12:1665-71 (2006)

PMID:11900250

Feldman BJ, Feldman D.

The development of androgen-independent prostate cancer.

Nat Rev Cancer 1:34-45 (2001)

PMID:15082523

Heinlein CA, Chang C.

Androgen receptor in prostate cancer.

Endocr Rev 25:276-308 (2004)

PMID:9422516

Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.

Androgen receptor gene and hormonal therapy failure of prostate cancer.

Am J Pathol 152:1-9 (1998)

PMID:10835690

Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.

Nat Med 6:703-6 (2000)

PMID:10453277

Macri E, Loda M.

Role of p27 in prostate carcinogenesis.

Cancer Metastasis Rev 17:337-44 (1998)

PMID:11750244

Steers WD.

5alpha-reductase activity in the prostate.

Urology 58:17-24; discussion 24 (2001)

PMID:8069858

Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.

Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.

Cancer Res 54:4920-6 (1994)

PMID:11527574

Grimes CA, Jope RS.

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

Prog Neurobiol 65:391-426 (2001)

PMID:15947972

Ryan AJ, Susil B, Jobling TW, Oehler MK.

Endometrial cancer.

Cell Tissue Res 322:53-61 (2005)

PMID:14747944

Lax SF.

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Virchows Arch 444:213-23 (2004)

PMID:16508724

Shiozawa T, Konishi I.

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Int J Clin Oncol 11:13-21 (2006)

PMID:17028294

Hecht JL, Mutter GL.

Molecular and pathologic aspects of endometrial carcinogenesis.

J Clin Oncol 24:4783-91 (2006)

PMID:11431710

Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J.

Molecular pathology of endometrial hyperplasia and carcinoma.

Hum Pathol 32:569-77 (2001)

PMID:15284264

Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH.

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.

J Clin Oncol 22:3126-32 (2004)

PMID:7585656

Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Cancer Res 55:5693-8 (1995)

PMID:16248975

Kim D, Chung J.

Akt: versatile mediator of cell survival and beyond.

J Biochem Mol Biol 35:106-15 (2002)

PMID:12711111

Sanchez-Cespedes M.

Dissecting the genetic alterations involved in lung carcinogenesis.

Lung Cancer 40:111-21 (2003)

PMID:11720739

Kaye FJ.

Molecular biology of lung cancer.

Lung Cancer 34 Suppl 2:S35-41 (2001)

PMID:12616528

Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF.

Apoptosis and lung cancer: a review.

J Cell Biochem 88:885-98 (2003)

PMID:11807782

Sartorius UA, Krammer PH.

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.

Int J Cancer 97:584-92 (2002)

PMID:16064138

Adhikary S, Eilers M.

Transcriptional regulation and transformation by Myc proteins.

Nat Rev Mol Cell Biol 6:635-45 (2005)

PMID:11463388

Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI.

A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1.

Mol Cell 7:639-50 (2001)

PMID:15109562

Buttery RC, Rintoul RC, Sethi T.

Small cell lung cancer: the importance of the extracellular matrix.

Int J Biochem Cell Biol 36:1154-60 (2004)

PMID:11559746

Yamada KM, Araki M.

Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis.

J Cell Sci 114:2375-82 (2001)

PMID:11905738

Rintoul RC, Sethi T.

The role of extracellular matrix in small-cell lung cancer.

Lancet Oncol 2:437-42 (2001)

PMID:12243753

Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B.

Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells.

Exp Cell Res 279:277-90 (2002)

PMID:12379883

Osada H, Takahashi T.

Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.

Oncogene 21:7421-34 (2002)

PMID:12741677

Yokota J, Nishioka M, Tani M, Kohno T.

Genetic alterations responsible for metastatic phenotypes of lung cancer cells.

Clin Exp Metastasis 20:189-93 (2003)

PMID:16870043

Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.

K-ras mutations in non-small-cell lung carcinoma: a review.

Clin Lung Cancer 8:30-8 (2006)

PMID:15948711

Pfeifer GP, Dammann R.

Methylation of the tumor suppressor gene RASSF1A in human tumors.

Biochemistry (Mosc) 70:576-83 (2005)

PMID:11902573

Altucci L, Gronemeyer H.

The promise of retinoids to fight against cancer.

Nat Rev Cancer 1:181-93 (2001)

PMID:10944551

Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF.

Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.

J Natl Cancer Inst 92:1303-7 (2000)

PMID:12867060

Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA.

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

Lung Cancer 41 Suppl 1:S29-42 (2003)

PMID:16112428

Panani AD, Roussos C.

Cytogenetic and molecular aspects of lung cancer.

Cancer Lett 239:1-9 (2006)

PMID:12407699

Mitsuuchi Y, Testa JR.

Cytogenetics and molecular genetics of lung cancer.

Am J Med Genet 115:183-8 (2002)

PMID:15942304

Breuer RH, Postmus PE, Smit EF.

Molecular pathology of non-small-cell lung cancer.

Respiration 72:313-30 (2005)

PMID:11895903

Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.

Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.

Clin Cancer Res 8:734-44 (2002)

PMID:16189154

Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K.

Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.

J Clin Pathol 58:1076-80 (2005)